Showing results (31-40 of 336) with videos related to
Sort By:
Pageof 34
American Journal of Hematology|June 10, 2018
Shifting Landscape of Hemophilia Therapy: Implications for Current Clinical Laboratory Coagulation AssaysHanny Al-Samkari, Stacy E CroteauBritish Journal of Clinical Pharmacology|July 23, 2018
An alternative intermittent eltrombopag dosing protocol for the treatment of chronic immune thrombocytopeniaHanny Al-Samkari, David J KuterAmerican Journal of Hematology|September 7, 2018
Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopeniaHanny Al-Samkari, David J KuterExpert Review of Hematology|April 11, 2023
Emerging data on thrombopoietin receptor agonists for management of chemotherapy-induced thrombocytopeniaAndrew B Song, Hanny Al-SamkariExpert Review of Clinical Immunology|July 6, 2022
An updated evaluation of avatrombopag for the treatment of chronic immune thrombocytopeniaAndrew B Song, Hanny Al-SamkariJournal of Blood Medicine|October 1, 2019
Avatrombopag for the treatment of immune thrombocytopenia and thrombocytopenia of chronic liver diseaseAbraham Z Cheloff, Hanny Al-SamkariBritish Journal of Haematology|March 5, 2025
Chemotherapy-induced thrombocytopenia: modern diagnosis and treatmentAndrew B Song, Hanny Al-SamkariAmerican Journal of Hematology|December 8, 2023
Avatrombopag for adults with early versus chronic immune thrombocytopeniaZain M Virk, Rebecca K Leaf, David J Kuter, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 22, 2020
Impact of ALK Rearrangement on Venous and Arterial Thrombotic Risk in NSCLCHanny Al-Samkari, Orly Leiva, Ibiayi Dagogo-Jack, et al.Therapeutic Advances in Hematology|January 6, 2022
Mitapivat, a novel pyruvate kinase activator, for the treatment of hereditary hemolytic anemiasHanny Al-Samkari, Eduard J van BeersPageof 34